Phaseline

Targets › IGF1

IGF1 (Insulin-like growth factor 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Dec 2027.

The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. May be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. (UniProt, P05019)

Open in Phaseline: the race on IGF1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Biohaven Pharmaceuticalstaldefgrobep alfa
Engineered IGF-1 analog; recombinant human IGF-1 receptor agonist
IGF1Phase 3Spinal Muscular AtrophyDec 2027

Conditions

Spinal Muscular Atrophy (1)

Modalities

small molecule (1)

Companies

Biohaven Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.